Chiesi signs $1.9B deal to acquire KalVista and its approved drug
Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KALV} in cash to buy the ...
April 29, 2026 09:25 AM EDT DealsPharma Chiesi signs $1.9B deal to acquire KalVista and its approved drug Kyle LaHucik Biotech Correspondent Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry’s vigorous spring shopping spree. The Italian pharma will … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that